Small cap health stocks commonly don’t pay dividends. But these ASX players have been handing out – not burning through – cash. You wouldn’t normally associate smaller health names with dividends, for obvious reasons. Either they lack profits, or they plough back whatever they’ve earned back into the R&D programs. For the latest health news, … [Read more…]
Small cap health stocks commonly don’t pay dividends. But these ASX players have been handing out – not burning through – cash. You wouldn’t normally associate smaller health names with dividends, for obvious reasons. Either they lack profits, or they plough back whatever they’ve earned back into the R&D programs. For the latest health news, … [Read more…]
There are clear signs the biotech sector is springing back to life after a disappointing 2022. These ASX stocks have shone in the past month. The benchmark US Biotech ETF index, also known as the XBI, has quietly risen by 3 per cent over the past six months. In Australia, the S&P/ASX 200 Health Care … [Read more…]
Zelira Therapeutics’ share price almost tripled after it announced its diabetic nerve pain drug outperformed multi-billion dollar Big Pharma drug, Lyrica. Top line results demonstrated that Zelira’s proprietary ZLT-L-007 drug outperformed Lyrica by achieving a significant reduction in NRS pain scores, indicating a decrease in symptom severity. ZLT-L-007 was found to be safe and well-tolerated, … [Read more…]